Treatment Effect of Niaspan, a Controlled-release Niacin, in Patients With Hypercholesterolemia: A Placebo-controlled Trial.

Academic Article


  • BACKGROUND: The present study was designed to determine the efficacy and safety of Niaspan (Kos Pharmaceuticals, Inc, Hollywood, FL), a new controlled-release formulation of niacin, in the treatment of primary hyperlipidemia, the occurrence and severity of flushing events, and potential adverse effects, particularly hepatotoxicity. METHODS AND RESULTS: The study was conducted as a multicenter, randomized, double-blind, placebo-controlled, parallel comparison of Niaspan in doses of 1000 mg/day and 2000 mg/day, administered once a day at bedtime. One hundred twenty-two patients with low-density lipoprotein cholesterol levels >4.14 mM/L (160 mg/dL) with dietary intervention and high-density lipoprotein cholesterol
  • Authors

    Digital Object Identifier (doi)

    Author List

  • Morgan JM; Capuzzi DM; Guyton JR; Centor RM; Goldberg R; Robbins DC; DiPette D; Jenkins S; Marcovina S
  • Start Page

  • 195
  • End Page

  • 202
  • Volume

  • 1
  • Issue

  • 3